A PHASE 3, MULTICENTER, DOUBLE-BLINDED, RANDOMIZED STUDY TO EVALUATE REGN7508, A FACTOR XI MONOCLONAL ANTIBODY, VERSUS ACETYLSALICYLIC ACID FOR PROPHYLAXIS OF SYMPTOMATIC VENOUS THROMBOEMBOLISM AFTER ELECTIVE TOTAL KNEE ARTHROPLASTY (ROXI-ASPEN)
- Registry ID
- R7508-DVT-24120
- Source registry
- HEALTH_CANADA
- Status
- Pending
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- REGENERON PHARMACEUTICALS INC
- Last update
- 2025-12-19
Conditions
Related clinical trials
- THE IMPACT OF ADDITIONAL POST-OPERATIVE DOSES OF TRANEXAMIC ACID ON PAIN, MOBILITY AND BLEEDING FOLLOWING TOTAL HIP AND TOTAL KNEE ARTHROPLASTY: A RANDOMIZED CONTROLLED TRIAL
- A PHASE 2, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL STUDY OF REGN9933, A FACTOR XI MONOCLONAL ANTIBODY, FOR PREVENTION OF VENOUS THROMBOEMBOLISM AFTER ELECTIVE, UNILATERAL, TOTAL KNEE ARTHROPLASTY
- PROTOCOL TITLE: EXTENDED VENOUS THROMBOEMBOLISM PROPHYLAXIS COMPARING RIVAROXABAN AND ASPIRIN TO ASPIRIN FOLLOWING TOTAL HIP AND KNEE ARTHROPLASTY EPCAT III
- OPIOID SPARING ANALGESIC STRATEGIES FOR ENHANCED RECOVERY AFTER TOTAL KNEE ARTHROPLASTY
- A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, MULTICENTER, ADAPTIVE DESIGN, DOSE-ESCALATION (PART 1) AND DOSE-RESPONSE (PART 2) STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS JNJ-64179375 VERSUS ORAL APIXABAN IN SUBJECTS UNDERGOING ELECTIVE TOTAL KNEE REPLACEMENT SURGERY
- A PHASE 3, MULTI-CENTER, LONG-TERM OBSERVATIONAL STUDY OF SUBJECTS FROM TANEZUMAB STUDIES WHO UNDERGO A TOTAL KNEE, HIP, OR SHOULDER REPLACEMENT
View on source registry